title: Impact of ELN recommendations in the management of first-line treated chronic myeloid leukaemia patients: a French cross-sectional study.
abstract: The availability of tyrosine kinase inhibitors has extended therapeutic options for chronic myeloid leukaemia (CML) patients. Monitoring recommendations and clinical response goals have recently been updated. The objective of this study was to describe the profile of CML patients in chronic phase currently receiving first-line therapy, including treatment, monitoring and response kinetics. A multicentre, cross-sectional, epidemiological survey in unselected chronic phase CML patients in France attending consultations during a one-month period was performed. 438 of 697 (62·8%) reported patients were currently receiving first-line treatment and were analysed. Imatinib was the most frequently received treatment (72·4% of patients). Retrospective cytogenetic and molecular assessments at 3, 6, 12 or 18 months were available in 88·4% of patients. At the 12-month assessment, 32·2% were not in major molecular response (MMR). At last assessment, among 355 patients with duration of treatment ≥ 12 months, 91·5% had achieved MMR and 66·5% were in deep molecular response. This study, performed in everyday practice population of CML patients, suggests that monitoring of molecular responses in real-life practice is aligned with European LeukaemiaNet recommendations. The majority of patients still receiving first-line treatment are in optimal response, with a few being classified as in the warning area or responding to failure.
authors.affiliation: Institut Bergonié, Bordeaux, France.
authors.forename: Gabriel
authors.initials: G
authors.lastname: Etienne
authors.affiliation: Institut Universitaire du Cancer, Toulouse, France.
authors.forename: Francoise
authors.initials: F
authors.lastname: Huguet
authors.affiliation: Hôpital de Brabois, Vandoeuvre-Les-Nancy, France.
authors.forename: Agnès
authors.initials: A
authors.lastname: Guerci-Bresler
authors.affiliation: Centre Hospitalier Lyon Sud, Pierre Benite, France.
authors.forename: Franck E
authors.initials: FE
authors.lastname: Nicolini
authors.affiliation: Clinique Sainte-Anne, HLA group, Strasbourg, France.
authors.forename: Frédéric
authors.initials: F
authors.lastname: Maloisel
authors.affiliation: Hôpital Claude Huriez, Lille, France.
authors.forename: Valérie
authors.initials: V
authors.lastname: Coiteux
authors.affiliation: Hôpital Pontchaillou, Rennes, France.
authors.forename: Charles
authors.initials: C
authors.lastname: Dauriac
authors.affiliation: Laboratoires Novartis France, Rueil-Malmaison, France.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Carpentier
authors.affiliation: Laboratoires Novartis France, Rueil-Malmaison, France.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Bourdeix
authors.affiliation: CHU Henri Mondor, Créteil, France.
authors.forename: Michel
authors.initials: M
authors.lastname: Tulliez
authors.affiliation: Centre Hospitalier Annecy Genevois, Pringy, France.
authors.forename: Pascale
authors.initials: P
authors.lastname: Cony-Makhoul
mesh_terms: D000368:Aged; D003430:Cross-Sectional Studies; D016903:Drug Monitoring; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000453:epidemiology; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D012074:Remission Induction / Q000379:methods; D013997:Time Factors
chemical_list: D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases
keywords: BCR-ABL1; chronic myeloid leukaemia; monitoring; real-life practice; tyrosine kinase inhibitor